摘要
目的评估患者开展三氧化二砷联合化疗治疗急性骨髓系白血病的临床价值和效果。方法该研究于2017年9月-2018年9月选取该院收治的52例急性髓系白血病患者作为研究对象,抽签法分组,每组26例,常规化疗治疗用于对照组,三氧化二砷联合化疗治疗用于观察组,关注两组患者有效救治统计值、骨髓抑制情况、不良反应统计值。结果观察组急性髓系白血病患者有效救治统计值(88.46%)对比对照组数据(61.53%)更高,差异有统计学意义(χ2=5.025 6,P=0.024 9<0.05)。观察组急性髓系白血病患者不良反应统计值(15.38%)对比对照组数据(42.30%)更低,差异有统计学意义(χ2=4.591 0,P=0.032 1<0.05);观察组治疗后急性髓系白血病患者白细胞数值(0.55±0.11)×10^9/L、血小板数值(25.65±0.36)×10^9/L、CD34+(2.56±0.01)%、P-gp(10.21±0.24)%优于对照组数据[(0.69±0.11)×10^9/L、(30.54±0.37)×109/L、(4.54±0.33)%、(18.51±0.57)%],差异有统计学意义(P<0.05);观察组急性髓系白血病患者生存时间(12.32±0.21)个月长于对照组相关数值(6.52±2.00)个月,差异有统计学意义(t=14.706 3,P=0.000 0<0.05)。结论将三氧化二砷联合化疗治疗使用于急性髓系白血病患者中可改善白细胞数值、血小板数值、CD34+、P-gp,减少不良反应。
Objective To evaluate myeleid leukemia the clinical value and effect of arsenic trioxide combined with chemotherapy in patients. Methods A total of 52 patients with acute myeloid leukemia admitted to our hospital from September 2017 to September 2018 were selected. By lottery grouping, they were divided into two grouops, with 26 cases in each group. Conventional therapy was used in the control group. And arsenic trioxide combined with chemotherapy was used in the observation group. Effective treatment of statistical values, bone marrow suppression, and adverse reaction statistics were recorded and compared. Results The effective treatment statistics(88.46%) of the patients with acute myeloid leukemia were higher than those of the control group(61.53%), and the difference was statistically significant(χ2=5.025 6, P=0.024 9<0.05). The statistical value of adverse reactions in patients with acute myeloid leukemia in the observation group(15.38%) was lower than that in the control group(42.30%), and the difference was statistically significant(χ2=4.591 0, P=0.032 1<0.05);after treatment,the acute myeloid in the observation group Leukemia patients with white blood cell counts(0.55 ± 0.11)×10^9/L, platelet values(25.65±0.36)×10^9/L, CD34+(2.56±0.01), P-gp(10.21±0.24)% better than the control data [(0.69±0.11)×10^9/L,(30.54±0.37)×10^9/L,(4.54±0.33)%,(18.51±0.57)%], the difference was statistically significant(P<0.05);the survival time of patients with acute myeloid leukemia in the observation group(12.32±0.21) months were longer than the control group(6.52±2.00)months, and the difference was statistically significant(t=14.706 3, P=0.000 0<0.05). Conclusion For acute myeloid leukemia patients, arsenic trioxide combined with chemotherapy can improve white blood cell count, platelet value, CD34+, P-gp, and reduce adverse reactions.
作者
赵永琴
董沙沙
ZHAO Yong-qin;DONG Sha-sha(The First People's Hospital of Jining City, Jining, Shandong Province, 272029 China)
出处
《系统医学》
2019年第15期4-6,共3页
Systems Medicine
关键词
局部亚低温
急性髓系白血病
临床疗效
Local hypothermia
Acute myeloid leukemia
Clinical efficacy
